JP2026502231A5 - - Google Patents

Info

Publication number
JP2026502231A5
JP2026502231A5 JP2025538315A JP2025538315A JP2026502231A5 JP 2026502231 A5 JP2026502231 A5 JP 2026502231A5 JP 2025538315 A JP2025538315 A JP 2025538315A JP 2025538315 A JP2025538315 A JP 2025538315A JP 2026502231 A5 JP2026502231 A5 JP 2026502231A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025538315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026502231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/143205 external-priority patent/WO2024141011A1/zh
Publication of JP2026502231A publication Critical patent/JP2026502231A/ja
Publication of JP2026502231A5 publication Critical patent/JP2026502231A5/ja
Pending legal-status Critical Current

Links

JP2025538315A 2022-12-31 2023-12-29 補体因子b阻害剤、その医薬組成物および使用 Pending JP2026502231A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202211737515 2022-12-31
CN202211737515.0 2022-12-31
CN202310699631 2023-06-13
CN202310699631.6 2023-06-13
PCT/CN2023/143205 WO2024141011A1 (zh) 2022-12-31 2023-12-29 补体因子b抑制剂及其药物组合物和应用

Publications (2)

Publication Number Publication Date
JP2026502231A JP2026502231A (ja) 2026-01-21
JP2026502231A5 true JP2026502231A5 (enExample) 2026-05-08

Family

ID=91716537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025538315A Pending JP2026502231A (ja) 2022-12-31 2023-12-29 補体因子b阻害剤、その医薬組成物および使用

Country Status (3)

Country Link
JP (1) JP2026502231A (enExample)
CN (1) CN120435467A (enExample)
WO (1) WO2024141011A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
CN103402996B (zh) * 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
CN104040422B (zh) * 2012-02-29 2016-04-13 宝理塑料株式会社 照相机模块用液晶性树脂组合物
SG11201406973PA (en) * 2012-05-04 2014-12-30 Novartis Ag Complement pathway modulators and uses thereof
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2016077240A2 (en) * 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
HRP20251596T1 (hr) * 2017-08-31 2026-01-30 Novartis Ag Nove upotrebe derivata piperidinil-indola
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도

Similar Documents

Publication Publication Date Title
JP2023516677A5 (enExample)
JPWO2020261723A5 (enExample)
JP2025146837A5 (enExample)
JP2019124943A5 (enExample)
JP2022013338A5 (enExample)
JP2021163968A5 (enExample)
JP2022027575A5 (enExample)
JPWO2022064931A5 (enExample)
JP2024512418A5 (enExample)
JPWO2022044675A5 (enExample)
JP2021503553A5 (enExample)
JPWO2021085142A5 (enExample)
JP2023150335A5 (enExample)
JPWO2022138440A5 (enExample)
JP2023005703A5 (enExample)
JPWO2021172087A5 (enExample)
JP2021013923A5 (enExample)
JP2020152824A5 (enExample)
JP2022058213A5 (enExample)
JP2024076480A5 (enExample)
JPWO2021132315A5 (enExample)
JPWO2021065243A5 (enExample)
JP2023176349A5 (enExample)
JP2022120819A5 (enExample)
JPWO2022201235A5 (enExample)